Changes of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) after autologous hematopoietic stem cell transplantation in multiple sclerosis

This publication has 13 references indexed in Scilit:

• Neutralizing antibodies against IFN- in multiple sclerosis: antagonization of IFN- mediated suppression of MMPs
  Brain, 2004
• Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS
  Neurology, 2004
• IFNβ lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS
  Neurology, 2003
• Matrix metalloproteinases in multiple sclerosis: Is it time for a treatment trial?
  Annals of Neurology, 2001
• Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon‐β therapy in relapsing and secondary‐progressive multiple sclerosis patients
  Annals of Neurology, 2001
• Expression of the Human Glucocorticoid Receptor α and β Isoforms in Human Respiratory Epithelial Cells and Their Regulation by Dexamethasone
  American Journal of Respiratory Cell and Molecular Biology, 2001
• Changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS
  Neurology, 1999
• Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis
  Brain, 1999
• Immune ablation followed by allogeneic or autologous bone marrow transplantation: A new treatment for severe autoimmune diseases?
  The International Journal of Cell Cloning, 1994
• Structural biochemistry and activation of matrix metalloproteases
  Current Opinion in Cell Biology, 1993